STOCK TITAN

Blue Water Biotech Inc - BWV STOCK NEWS

Welcome to our dedicated news page for Blue Water Biotech (Ticker: BWV), a resource for investors and traders seeking the latest updates and insights on Blue Water Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Blue Water Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Blue Water Biotech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none
-
Rhea-AI Summary
Blue Water Biotech, Inc. has been granted a license by the Ohio State Board of Pharmacy to operate as a pharmaceutical wholesaler in the state. This is the first license granted to the company since it established itself as a commercial stage pharmaceutical company. Blue Water recently acquired FDA-approved pharmaceutical assets and has signed agreements for commercialization and marketing of its products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
fda approval
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.31%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.31%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
none
-
Rhea-AI Summary
Blue Water Biotech, Inc. has signed an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC to purchase six FDA-approved assets across multiple indications for $8.5 million in cash and 1.0 million restricted shares of Blue Water's common stock. The assets include patents related to ZONTIVITY®, two antibiotic otic products, and other medications for hypertension and pain management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
62.03%
Tags
acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
Blue Water Biotech Inc

Nasdaq:BWV

BWV Rankings

BWV Stock Data

3.41M
13.90M
17.69%
23.45%
0.13%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cincinnati

About BWV

developed by scientists at the prestigious oxford university in the uk, our vaccine protects against all influenza strains. it targets parts of the virus that are easy to induce a protective immune response against but also limited in variability. these regions of the virus were shown in thompson et al 2018 to direct the antigenic evolution of the influenza virus and therefore make ideal vaccine targets. the vaccine thus negates the need for (i) annual vaccination, providing potentially life-long protection against flu, and (ii) reformulation of the vaccine every few years.